Meeting
2021 ASCO Annual Meeting
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
Authors
Mariam Jamal-Hanjani
University College London, London, United Kingdom
Mariam Jamal-Hanjani , Alastair Greystoke , Fiona Thistlethwaite , Yvonne J. Summers , Jennifer Allison , Judith Cave , Kim Orchard , Christian Ottensmeier , Gary Middleton , Leila Khoja , Michael Grant , Shreenal Patel , Jane Robertson , Karl Peggs , Martin Forster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04032847
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9138)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9138
Abstract #
TPS9138
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.
First Author: Jason Alan Chesney
Poster
2018 ASCO Annual Meeting
A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.
First Author: Sylvia Mina Lee
Poster
2022 ASCO Annual Meeting
IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.
First Author: Alexander Starodub
Poster
2022 ASCO Annual Meeting
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
First Author: Marcelo Vailati Negrao